Applied to cancer immunotherapy, this orthogonal framework was implemented in embryonic stem cells (ESCs) to deliver a dual-function circuit: bezafibrate simultaneously induces (1) tumor antigen-GM-CSF fusions to enhance immunogenicity and (2) PD-L1 nanobodies for checkpoint blockade, creating a synergistic response (84) (Figure 3D). The gene discussed is CSF2; the disease is neoplasm.